IL2 and neoplasm: NKTR-214 is an investigational, first-in-class, CD122 preferential agonist that functions as a pegylated recombinant interleukin-2 (IL-2) with cellular effects in activation of CD8+ T and natural killer (NK) cells without unwanted expansion of T regulatory (Treg) cells in the tumor microenvironment [28].